Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: The insulin resistance atherosclerosis study

Diabetes

Volumn 51, Issue 4, 2002, Pages 1131-1137

  Festa, Andreas ^a   D'Agostino Jr , Ralph ^b   Tracy, Russell P ^c   Haffner, Steven M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BODY FAT; CHRONIC INFLAMMATION; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR;

EID: 0036230414     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.4.1131     Document Type: Article

References (48)

1. C-reactive protein as a cardiovascular risk factor. More than an epiphenomenon?
2. Diabetes and cardiovascular disease: The "common soil" hypothesis
3. Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease: Putative association via common antecedents-further evidence from the Whitehall Study
4. Atherosclerosis: An inflammatory disease
5. Is type II diabetes mellitus a disease of the innate immune system?
6. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): A cohort study
7. Factor VIII and other hemostasis variables are related to incident diabetes in adults
8. Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: A balanced overview
9. Chronic subclinical inflammation as part of the insulin resistance syndrome
10. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction
11. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS)
12. Involvement of the hemostatic system in the insulin resistance syndrome: A study of 1500 patients with angina pectoris
13. The cardiovascular risk factor plasminogen activator inhibitor type I is related to insulin resistance
14. The Insulin Resistance Atherosclerosis Study (IRAS): Objectives, design and recruitment results
15. Assessment of insulin sensitivity in vivo
16. MINMOD: A computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test
17. Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference interval and epidemiological applications
18. The measurement of fibrinogen in population-based research: Studies on instrumentation and methodology
19. Gerinnungsphysiologische schnellmethode zur Bestimmung des fibrinogens
20. Sample preparation for plasma measurement of plasminogen activator inhibitor-1 antigen in large population studies
21. Measurement of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzyme-linked immunosorbent assays
22. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients
23. Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture
24. Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes
25. Islet cell antibodies identify latent type 1 diabetes in patients aged 35-75 years at diagnosis
26. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult)
27. Increased adipose tissue expression of tumour necrosis factor-α in human obesity and insulin resistance
28. Human subcutaneous adipose tissue secretes interleukin-6 but not tumour necrosis factor-α in vivo
29. Regulation of the acute phase response by cytokines
30. Tumor necrosis factor-α is a key component in the obesity-linked elevation of plasminogen activator-inhibitor 1
31. Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes
32. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II
33. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production
34. Determinants of plasma levels of plasminogen activator inhibitor-1
35. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): Relation to reduced fetal growth
36. The relation of small head circumference and thinness at birth to death from cardiovascular disease in adult life
37. Birth weight and the insulin resistance syndrome: Association of low birth weight with truncal obesity and raised plasminogen activator inhibitor-1 but not with abdominal obesity or plasma lipid disturbances
38. Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women
39. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first myocardial infarction in both men and women
40. Prevention of type-2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise
41. Impact of smoking, physical training and weight reduction on FVII, PAI-1 and hemostatic markers in sedentary men
42. Wu KK Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults
43. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects
44. Design and methods for a clinical trial in the prevention of type 2 diabetes
45. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction
46. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
47. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial